pentobarbital will decrease the extent or effect of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Solid or reasonable CYP3A inducers could minimize cobimetinib systemic exposure by >eighty% and minimize its efficacy. Find how